CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 52 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2019. The put-call ratio across all filers is 0.70 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,908,650 | -20.6% | 69,355 | -2.1% | 0.00% | -50.0% |
| Q2 2023 | $2,403,398 | -43.3% | 70,834 | -39.9% | 0.00% | -33.3% |
| Q1 2023 | $4,242,222 | +29.5% | 117,905 | +60.4% | 0.00% | +50.0% |
| Q4 2022 | $3,275,761 | -41.6% | 73,497 | -63.1% | 0.00% | -50.0% |
| Q3 2022 | $5,605,000 | -27.2% | 199,412 | -30.2% | 0.00% | -20.0% |
| Q2 2022 | $7,702,000 | -7.1% | 285,677 | +17.3% | 0.01% | 0.0% |
| Q1 2022 | $8,295,000 | -28.2% | 243,519 | -18.6% | 0.01% | -16.7% |
| Q4 2021 | $11,555,000 | +95.8% | 299,048 | +173.6% | 0.01% | +100.0% |
| Q3 2021 | $5,902,000 | +46.8% | 109,309 | -9.1% | 0.00% | +50.0% |
| Q2 2021 | $4,021,000 | +12.6% | 120,254 | -30.6% | 0.00% | 0.0% |
| Q1 2021 | $3,570,000 | +472.1% | 173,278 | +386.9% | 0.00% | – |
| Q4 2020 | $624,000 | +5100.0% | 35,591 | +524.4% | 0.00% | – |
| Q3 2019 | $12,000 | -33.3% | 5,700 | -15.2% | 0.00% | – |
| Q2 2019 | $18,000 | – | 6,718 | +33.9% | 0.00% | – |
| Q1 2019 | $0 | – | 5,018 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 2,600,000 | $88,218,000 | 12.13% |
| Octagon Capital Advisors LP | 759,898 | $25,783,339 | 3.59% |
| TSP Capital Management Group, LLC | 251,895 | $8,546,800 | 3.08% |
| ACUTA CAPITAL PARTNERS, LLC | 122,343 | $4,151,098 | 2.81% |
| 5AM Venture Management, LLC | 310,270 | $10,527,461 | 2.62% |
| COMMODORE CAPITAL LP | 631,665 | $21,432,393 | 2.41% |
| RTW INVESTMENTS, LP | 3,463,201 | $117,506,410 | 2.24% |
| Eversept Partners, LP | 785,740 | $26,660,158 | 2.23% |
| Redmile Group, LLC | 1,696,004 | $57,545,416 | 2.21% |
| Affinity Asset Advisors, LLC | 87,031 | $2,952,962 | 1.03% |